Shuodi Bio completed a new round of financing

Soldier Biosciences is a clinical-stage biopharmaceutical developer dedicated to the use of advanced computing and structure-based technologies to develop medicines that change the fate of patients. Soldi uses advanced computing and structure-based technologies to develop life-changing medicines for patients. Following last year’s $100 million Series B round, the company closed an oversubscribed $33 million in financing. New investors included in the financing include Deep Track Capital and Piper Heartland Healthcare Capital. Proceeds from the financing will be used to advance the leading programs in the clinical research of Soldi Biosciences and expand the application of its next-generation structure-based drug discovery platform to drive innovation in G protein-coupled receptor (GPCR)-targeted therapies.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.